Good MorningEquity markets rebounded from Wednesday's Fed-induced sell-off, but Thursday's action gives little reason to think the selling is over. The S&P gained less than 1% to trade in the lower half of the previous day's range, creating a Harami candle pattern signaling the sell-off has the potential to gain strength. A move to retest Wednesday's low is likely, and a move to new lows is possible. The market could fall as low as 5,700 in that scenario before the S&P 500 hits firm support.
Today will be a test for the market. The PCE Price Index is due and expected to confirm inflation is rising. A hot report will strengthen the Fed's resolve, possibly leading them to reduce the rate cut outlook again and give the market a reason to sell. The silver lining is that the underlying causes of high inflation are demand and economic health, which are drivers of corporate earnings and bullish for stocks. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Technology | | Investors interested in Micron Technology (NASDAQ: MU) should cheer the fact that its stock tanked following the FQ1 2025 earnings report. The move is a knee-jerk reaction to mixed results and guidance that point to near-term weakness and long-term strength, driven by its shift to AI.
The legacy... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Business Services | | In the midst of companies looking to implement AI and investors looking for a way to profit from the trend, up-and-coming AI firms continue to pop up. Below, I’ll detail three small-cap AI stocks to watch out for in 2025. Two have had great 2024s and are looking to continue their strong showin... Read the Full Story |
|
Energy | |
As years go by, 2024 has not been a great one for shares of SolarEdge Technologies Inc (NASDAQ: SEDG). The $800 million market cap stock is down 85% since the start of January, which means it’s back trading at 2016 levels. For any investor that was involved in SolarEdge in the 8 years since ... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Energy | | At a time when many stocks are objectively and historically overvalued, many investors are wondering where they should put their investable capital in 2025. Some stocks that should attract your attention are trading for less than $10. These stocks allow investors to accumulate a significant number o... Read the Full Story |
|
Technology | |
The most upgraded stocks at year’s end in 2024 are NVIDIA (NASDAQ: NVDA), Amazon (NASDAQ: AMZN), and Meta Platforms (NASDAQ: META). Each received more than 120 positive revisions, including price target increases and upgrades that have lifted their markets significantly. The question is whet... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Industrials | |
The industrials sector has been in a period of contraction for most of 2023 and 2024, with sharply mixed performance among different companies during that time. Some firms have thrived, like power management giant Eaton Corp. plc (NYSE: ETN), with its nearly 50% returns in the year leading to Dece... Read the Full Story |
|
Business Services | |
Shares of ABM Industries (NYSE: ABM) fell more than 7% after its FQ4 release, opening an attractive entry for dividend growth investors. This Dividend King fell to a critical support level near the middle of its long-term trading range, where support is likely to be robust.
The Q4 report offers l... Read the Full Story |
|
Utilities | |
The green energy sector is experiencing rapid expansion, driven by escalating global concerns about climate change, supportive government policies, and continuous technological innovation. This growth presents considerable investment opportunities but also significant challenges. While large-cap c... Read the Full Story |
|
Business Services | |
When investors look to find the next big opportunity to invest their capital, they often focus on what’s popular at the time or having the best price action in the so-called “popularity contest” that both Warren Buffett and Keynes referred to in their work. They also mentioned th... Read the Full Story |
|
Business Services | |
Aurora Innovation Inc (NASDAQ: AUR) has been turning heads this week, with a 14% jump in Monday's session that made it one of the day's top performers. It added to a rally that kicked off back in the summer of 2023 but has really been stretching its legs in recent months. The self-driving vehicl... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. | | View Today's Stock Pick |
|
